Ignacio Soriano

Dr. Ignacio Soriano


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
KSKitty Sherwood
Kitty Sherwood
JWJoseph C. Ward
Joseph C. Ward
ISIgnacio Soriano
Ignacio Soriano
LMLynn Martin
Lynn Martin
ACArchie Campbell
Archie Campbell
ITIan Tomlinson
Ian Tomlinson
DNA repair defects underlie many cancer syndromes. We tested whether de novo germline mutations (DNMs) are increased in families with germline defects in polymerase proofreading or base excision repair. A parent with a single germline POLE or POLD1 mutation, or biallelic MUTYH mutations, had 3-4 fold increased DNMs over sex-matched controls. POLE had the largest effect. The DNMs carried mutational signatures of the appropriate DNA repair deficiency. No DNM increase occurred in offspring of MUTYH heterozygous parents. Parental DNA repair defects caused about 20–150 DNMs per child, additional to the ~60 found in controls, but almost all extra DNMs occurred in non-coding regions. No increase in post-zygotic mutations was detected, excepting a child with bi-allelic MUTYH mutations who was excluded from the main analysis; she had received chemotherapy and may have undergone oligoclonal haematopoiesis. Inherited DNA repair defects associated with base pair-level mutations increase DNMs, but phenotypic consequences appear unlikely.

6 July 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
ISIgnacio Soriano
Ignacio Soriano
Enrique VázquezEnrique Vázquez
Enrique Vázquez
NLNagore De Leon
Nagore De Leon
SBSibyl Bertrand
Sibyl Bertrand
EHEllen Heitzer
Ellen Heitzer
SKStephen Kearsey
Stephen Kearsey
Somatic and germline mutations in the proofreading domain of the replicative DNA polymerase ε (POLE-exonuclease domain mutations, POLE-EDMs) are frequently found in colorectal and endometrial cancers and, occasionally, in other tumours. POLE-associated cancers typically display hypermutation, and a unique mutational signature, with a predominance of C > A transversions in the context TCT and C > T transitions in the context TCG. To understand better the contribution of hypermutagenesis to tumour development, we have modelled the most recurrent POLE-EDM (POLE-P286R) in Schizosaccharomyces pombe. Whole-genome sequencing analysis revealed that the corresponding pol2-P287R allele also has a strong mutator effect in vivo, with a high frequency of base substitutions and relatively few indel mutations. The mutations are equally distributed across different genomic regions, but in the immediate vicinity there is an asymmetry in AT frequency. The most abundant base-pair changes are TCT > TAT transversions and, in contrast to human mutations, TCG > TTG transitions are not elevated, likely due to the absence of cytosine methylation in fission yeast. The pol2-P287R variant has an increased sensitivity to elevated dNTP levels and DNA damaging agents, and shows reduced viability on depletion of the Pfh1 helicase. In addition, S phase is aberrant and RPA foci are elevated, suggestive of ssDNA or DNA damage, and the pol2-P287R mutation is synthetically lethal with rad3 inactivation, indicative of checkpoint activation. Significantly, deletion of genes encoding some translesion synthesis polymerases, most notably Pol κ, partially suppresses pol2-P287R hypermutation, indicating that polymerase switching contributes to this phenotype.

23 January 2023 in Gastroenterology
Verified
Journal Article
Open access
PDF file
JGJurriaan van Ginkel
Jurriaan van Ginkel
ITIan Tomlinson
Ian Tomlinson
ISIgnacio Soriano
Ignacio Soriano
Using colorectal cancer (CRC) as a model, we review some of the insights into cancer evolution afforded by cancer sequencing. These include: non-linear and neutral evolution; polyclonality of driver mutations and parallel evolution in adenomas, although only rarely in carcinomas; the ability of mutational processes to shape evolution against the force of selection; the presence of rare driver genes that function in the same signalling pathways as the longstanding canonical drivers; and the existence of selective windows that constrain the functional effects of cancer driver mutations within limits. Many of these nascent evolutionary paradigms are potentially important for treating CRCs as well as understanding their development.

22 June 2025 in The Journal of Pathology
Verified
Journal Article
Open access
JWJoseph C Ward
Joseph C Ward
MMMelissa Morgan
Melissa Morgan
JWJames Wood
James Wood
CWConnor Woolley
Connor Woolley
AMAlbert Antao Nobre de Menezes
Albert Antao Nobre de Menezes
ITIan Tomlinson
Ian Tomlinson
The CpG island methylator phenotype (CIMP) occurs in many colorectal cancers (CRCs). CIMP is closely associated with global hypermethylation and tends to occur in proximal tumours with microsatellite instability (MSI), but its origins have been obscure. A few CRCs carry oncogenic (gain‐of‐function) mutations in isocitrate dehydrogenase IDH1 . Whilst IDH1 is an established CRC driver gene, the low frequency of IDH1 ‐mutant CRCs (about 0.5%) has meant that the effects and molecular covariates of those mutations have not been established. We first showed computationally that IDH2 is also a CRC driver. Using multiple public and in‐house CRC datasets, we then identified IDH mutations at the hotspots ( IDH1 codons 132 and IDH2 codons 140 and 172) frequently mutated in other tumour types. Somatic IDH mutations were associated with BRAF mutations and expression of mucinous/goblet cell markers, but not with KRAS mutations or MSI. All IDH‐mutant CRCs were CIMP‐positive, mostly at a high level. Cell and mouse models showed that IDH mutation was plausibly causal for DNA hypermethylation. Whilst the aetiology of hypermethylation generally remains unexplained, IDH‐mutant tumours did not form a discrete methylation subcluster, suggesting that different underlying mechanisms can converge on similar final methylation phenotypes. Although further analysis is required, IDH mutations may be the first cause of hypermethylation to be identified in a common cancer type, providing evidence that CIMP and DNA methylation represent more than aging‐related epiphenomena. Cautious exploration of mutant IDH inhibitors and DNA demethylating agents is suggested in managing IDH‐mutant CRCs. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

15 October 2025 in Cancer Research
Verified
Journal Article
Open access
MGMeritxell Brunet Guasch
Meritxell Brunet Guasch
NFNathalie A. Feeley
Nathalie A. Feeley
ISIgnacio Soriano
Ignacio Soriano
STSteve Thorn
Steve Thorn
ITIan P.M. Tomlinson
Ian P.M. Tomlinson
TATibor Antal
Tibor Antal
Dysregulation of the tumor suppressor gene adenomatous polyposis coli (APC) is a canonical step in colorectal cancer development by promoting activation of the WNT/β-catenin pathway. Curiously, most colorectal tumors carry biallelic mutations that result in only partial loss of APC function, suggesting that a “just-right” level of APC inactivation, and hence WNT signaling, provides the optimal conditions for tumorigenesis. Mutational processes act variably across the APC gene, which could contribute to the bias against complete APC inactivation. In this study, we propose a mathematical model to quantify the tumorigenic effect of biallelic APC genotypes, controlling for somatic mutational processes. Analysis of sequence data from >2,500 colorectal cancers showed that APC genotypes resulting in partial protein function confer about 50 times higher probability of progressing to cancer compared with complete APC inactivation. The optimal inactivation level varied with anatomic location and additional mutations of WNT pathway regulators. Assessment of the regulatory effects of secondary alterations in WNT drivers in combination with APC in vivo provided evidence that AMER1 mutations increase WNT activity in tumors with suboptimal APC genotypes. The fitness landscape of APC inactivation was consistent across microsatellite unstable and polymerase epsilon–deficient colorectal cancers and tumors in patients with familial adenomatous polyposis. Together, these findings suggest a general “just-right” optimum for APC inactivation and WNT signaling, pointing to WNT hyperactivation as a potential vulnerability in cancer. Significance: Mathematical modeling of tumor development with different APC genotypes substantiates the “just-right” APC inactivation model and suggests alterations in secondary WNT regulators enhance WNT activity in colorectal cancers with suboptimal APC genotypes. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI .

25 August 2025 in Genome Medicine
Verified
Journal Article
Open access
PDF file
JWJoseph C. Ward
Joseph C. Ward
ISIgnacio Soriano
Ignacio Soriano
STSteve Thorn
Steve Thorn
JFJuan Fernández-Tajes
Juan Fernández-Tajes
KSKitty Sherwood
Kitty Sherwood
ITIan Tomlinson
Ian Tomlinson
Background: Single base substitution (SBS) mutations, particularly C > T and T > C, are increased owing to unrepaired DNA replication errors in mismatch repair-deficient (MMRd) cancers. Excess CpG > TpG mutations have been reported in MMRd cancers defective in mismatch detection (dMutSα), but not in mismatch correction (dMutLα). Somatic CpG > TpG mutations conventionally result from unrepaired spontaneous deamination of 5’-methylcytosine throughout the cell cycle, causing T:G mismatches and signature SBS1. It has been proposed that MutSα detects those mismatches, prior to error correction by base excision repair (BER). However, other evidence appears inconsistent with that hypothesis: for example, MutSα is specifically expressed in S/G2 phases of the cell cycle, and defects in replicative DNA polymerase proofreading specifically cause excess CpG > TpG mutations in signature SBS10b. Methods: We analysed mutation spectra and COSMIC mutation signatures in whole-genome sequencing data from 1803 colorectal cancers (164 dMutLα, 20 dMutSα) and 596 endometrial cancers (103 dMutLα, 9 dMutSα) from the UK 100,000 Genomes Project. We mapped each C > T mutation to its genomic features, including normal DNA methylation state, replication timing, transcription strand, and replication strand, to investigate the mechanism(s) by which these mutations arise. Results: We confirmed that dMutSα tumours specifically had higher CpG > TpG burdens than dMutLα tumours. We could fully reconstitute the observed dMutSα CpG > TpG mutation spectrum by adding CpG > TpG mutations in proportion to their SBS1 activity to the dMutLα spectrum. However, other evidence indicated that the SBS1 excess in dMutSα cancers did not come from 5’-methylcytosine deamination alone: non-CpG C > T mutations were also increased in dMutSα cancers; and, in contrast to tumours deficient in BER, CpG > TpG mutations were biased to the leading DNA replication strand, at similar levels in dMutSα and dMutLα cancers, suggesting an origin in DNA replication. Other substitution mutations usually corrected by BER were not increased in dMutSα tumours. Conclusions: There is a CpG > TpG and SBS1 excess specific to dMutSα MMRd tumours, consistent with previous reports, and we find a general increase in somatic C > T mutations. Contrary to some other studies, the similar leading replication strand bias in both dMutSα and dMutLα tumours indicates that at least some of the excess CpG > TpG mutations arise via DNA replication errors, and not primarily via the replication-independent deamination of 5’-methylcytosine.